|August 18, 2014|
|08:52 EDT||PTCT||PTC Therapeutics price target raised to $43 from $34 at Roth Capital|
Roth Capital increased its price target on PTC as the firm thinks that, based on recent favorable developments, the company's spinal muscular atrophy program is gaining steam. Roth believes that the compounds identified by PTC can be expanded to other neuro-muscular disorders. Roth reiterates a Buy rating on the stock.
News For PTCT From The Last 14 Days
Check below for free stories on PTCT the last two weeks.
|September 17, 2014|
|08:04 EDT||PTCT||PTC Therapeutics prepares launch of Translarna in Europe |
Subscribe for More Information
|September 15, 2014|
|09:59 EDT||PTCT||On The Fly: Analyst Initiation Summary|
Today's noteworthy initiations include: American Realty (ARCP) initiated with an Overweight at JPMorgan... Athlon Energy (ATHL) initiated with a Buy at KLR Group... Capital Product (CPLP) initiated with a Buy at Jefferies... Continental Resources (CLR) initiated with a Buy at Canaccord... Costco (COST) initiated with a Buy at Citigroup... Infinera (INFN) initiated with an Outperform at Barrington... NRG Yield (NYLD) initiated with an Outperform at RBC Capital... PTC Therapeutics (PTCT) initiated with a Buy at Deutsche Bank... Power Solutions (PSIX) initiated with an Outperform at Northland... ServiceNow (NOW) initiated with an Outperform at William Blair... Target (TGT) initiated with a Neutral at Citigroup... Team (TISI) initiated with a Neutral at Sidoti... VeriFone (PAY) initiated with a Buy at Monness Crespi... Wal-Mart (WMT) initiated with a Neutral at Citigroup... Whiting Petroleum (WLL) initiated with a Buy at Canaccord... Winnebago (WGO) initiated with an Outperform at BMO Capital.
|05:45 EDT||PTCT||PTC Therapeutics initiated with a Buy at Deutsche Bank|
|September 9, 2014|
|08:07 EDT||PTCT||PTC Therapeutics completes enrollment of Phase 3 trial of Translarna|
PTC Therapeutics announced that it has completed enrollment of ACT DMD, the Phase 3 confirmatory trial of Translarna, or ataluren, for patients with nonsense mutation Duchenne muscular dystrophy, or nmDMD. Top-line data from the trial is expected in the second half of 2015 and will support further approvals globally, following European approval received earlier this year.